Xoma Royalty, a drug royalty specialist, has acquired struggling biotech Mural Oncology for approximately $36 million, marking its fourth acquisition since June 2025. This move continues Xoma’s strategic approach of purchasing and winding down underperforming or 'zombie' biotech companies. Such consolidation strategies reflect ongoing shifts in the biotech sector focused on portfolio optimization and cost management amid challenging market conditions.